media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Evidence-based breakthrough! Traditional Chinese medicine for anti-fibrosis selected again for the National Science and Technology Major Project

In the field of liver disease, the long-term damage caused by the vast majority of chronic liver diseases leads to the occurrence and development of liver fibrosis. The degree and rate of progression of liver fibrosis directly affect the risk of cirrhosis and liver cancer. Therefore, effective intervention and reversal of the liver fibrosis process are of vital clinical significance. Unlike other disease treatment areas, traditional Chinese medicine (TCM) has shown unique potential in this field. Recently, Ganxianle® , a modern TCM product under Baiyang Pharmaceuticals , which strengthens the body’s resistance and removes blood stasis, participated in the National Science and Technology Major Project led by Beijing Ditan Hospital affiliated to Capital Medical University—”Research on the Comprehensive Evaluation System and Optimization Scheme of the Whole Chain of Integrated Traditional Chinese and Western Medicine Treatment to Reverse Hepatitis B Cirrhosis”. The selection criteria for the National Science and Technology Major ...
- Source: drugdu
- 50
- February 3, 2026
Amgen terminates development of a Phase 3 clinical antibody drug

recently announced the termination of its collaboration agreement with Japanese pharmaceutical company Kyowa Kirin regarding rocatinlimab, a candidate drug for autoimmune diseases. Five years ago, Amgen paid a $400 million upfront payment and committed to milestone payments of up to $850 million to acquire the global (excluding Japan) rights to develop, manufacture, and commercialize rocatinlimab. According to a press release from Kyowa Kirin, the termination of this agreement was based on Amgen’s strategic priorities regarding its product portfolio . Kyowa Kirin will regain global rights to rocatinlimab. Rocatinlimab (AMG451/KHK4083) is a blocking OX40 antibody with ADCC activity developed by Kyowa Kirin . Previously, rocatinlimab met all co-primary and key secondary endpoints in two Phase 3 clinical trials for atopic dermatitis (AD), ROCKET-IGNITE and ROCKET-HORIZON, including skin clearance rate, which met the requirements for US regulatory filing. In the ROCKET-IGNITE study, 42.3% and 36% of patients receiving 300 mg and 150 ...
- Source: drugdu
- 41
- February 3, 2026
Bio Korea

Organiser：Korea Health Industry Development Institute Time：April 29 – May 1, 2026 Address：513 Yeongdong-daero, Gangnam District, Seoul, South Korea Exhibition hall： COEX Convention & Exhibition Center Product range: Bioprocess Engineering: Bioreactors, bioreactor equipment, bioprocess development, GLP/GMP, bioreactor analysis, aseptic techniques, downstream processing, ultrapure water systems, laboratory equipment, logistics, measurement and control Bioinformatics: Databases, molecular bioinformatics, modeling software/simulation software, chemometrics, bio-evolutionary strategies, drug certification software, data mining, scientific software, laboratory information management systems, laboratory electronic record systems, personal software services, process optimization software, knowledge management, image processing Bioanalysis: Process analysis, biosensors, genomics, proteomics, and other omics, diagnostics, electrophoresis/capillary electrophoresis, biotechnical services, pharmaceuticals, diagnostics, biopharmaceutical applications About Bio Korea ： Bio Korea, established in 2006, is South Korea’s and even Asia’s premier event in the biotechnology industry. The event consists of several parts, including the main conference, business forums, exhibitions, pharmaceutical sub-exhibition areas with special events, medical device sub-exhibition areas with special events, ...
- Source: drugdu
- 45
- February 3, 2026
PotentiaBiotech Supports CSPC Group in Obtaining IND Approval for China’s First In Vivo CAR-T Therapy

On January 29, 2026, PotentiaBiotech supported CSPC Group in obtaining implied approval for clinical trials from the National Medical Products Administration (NMPA) for its independently developed SYS6055 Injection, with the application acceptance number: CXSL2500947. This marks China’s first in vivo CAR-T therapy to receive clinical trial approval, indicated for relapsed/refractory aggressive B-cell lymphoma. PotentiaBiotech extends its warm congratulations on this milestone achievement! Picture 1: From the Wechat Public Account “PotentiaBiotech” About CSPC Group CSPC Holding Group Co., Ltd. was established in 1997. Guided by its long-standing philosophy of “Developing Quality Medicines for China and Benefiting People Worldwide”, the company has sustained double-digit growth in its core operating indicators for many years through innovation-driven development. It has now grown into an international innovation-oriented enterprise with 28,000 employees. Its listed subsidiary on the Hong Kong Stock Exchange (01093.HK) is a constituent stock of the Hang Seng Index, and ranks 19th globally in ...
- Source: drugdu
- 60
- February 2, 2026
Li Auto Frontier Dynamics Secures $200 Million Series B Financing, Cornerstone Ventures Participates as Investor

LimX Dynamics announced the completion of a $200 million Series B financing round, with Cornerstone Capital as a participant. With full-stack technology, we grasp the pivotal capabilities that drive embodied intelligence toward real-world deployment. As we step into 2026, with the strong support of our existing and new shareholders as well as partners, LimX Dynamics will scale up its investment in R&D and market expansion. Grounded in three core competencies: proprietary hardware design and manufacturing, cerebellum foundation models, and the embodied Agentic OS, LimX Dynamics focuses on breakthroughs in the core technology of fusing the “brain and cerebellum” for embodied intelligence. The company advances original innovation in general-purpose humanoid robots and modular base robots, and will further expand its presence in both the Chinese and global markets through product engineering and the development of a supply chain ecosystem. Over the past two months, LimX Dynamics has successively launched two pivotal ...
- Source: drugdu
- 53
- February 2, 2026
Driven by drugs for lowering blood sugar and losing weight, the export value of Chinese Western medicine preparations has reached a record high

China has always been a major exporter of raw pharmaceutical materials, and how to develop the export of Western medicine products towards higher added value has attracted much attention. 　　Chinese medicineData released on January 29 by the China Chamber of Commerce for Health Products Import and Export shows that in 2025, China’s exports of Western medicine preparations amounted to US$8.841 billion, a year-on-year increase of 27.29%. Among them, the export value of preparations accounted for a record high of 15.85% of the total exports of Western medicine products. 　　Furthermore, in 2025, the export value of pharmaceutical preparations accounted for 7.94% of the total export value of pharmaceutical products, showing a significant upward trend. This reflects the continuous upgrading of China’s pharmaceutical industry from upstream intermediates and raw materials to downstream high-value-added fields such as pharmaceutical preparations. 　　In 2025, China’s exports of Western medicine preparations showed a trend ...
- Source: https://finance.eastmoney.com/a/202601303636737935.html
- 57
- February 2, 2026
Chengdu Pioneer and Kangzhe Pharmaceutical have reached a cooperation agreement to leverage the DEL and HAILO platforms to empower the development of multi-target innovative drugs

According to Chengdu Pioneer…According to reports, Chengdu Pioneer recently signed a cooperation agreement with a subsidiary of Kangzhe Pharmaceutical Holdings Limited (hereinafter referred to as ” Kangzhe Pharmaceutical “). Chengdu Pioneer will provide Kangzhe Pharmaceutical with innovative drugs targeting multiple specific targets.The company provides development services. Chengdu Pioneer will rely on its DNA-encoded compound library (DEL) technology platform and Qualcomm…HAILO, an AI-driven molecular optimization platform, provides Kangzhe Pharmaceuticals with a one-stop development service from target validation to preclinical compound candidates (PCCs). This initiative aims to efficiently generate drug candidates with “first-in-class” (FIC) or “best-in-class” (BIC) potential.
- Source: https://finance.eastmoney.com/a/202601303636285775.html
- 53
- February 2, 2026
【EXPERT Q&A】Why is it necessary to obtain a medical device business license when selling medical devices?

Drugdu.com expert’s response: Selling medical devices requires obtaining a Medical Device Business License, which is based on a comprehensive consideration of legal mandatory requirements, ensuring product quality and safety, maintaining market order, enhancing corporate competitiveness, avoiding operational risks, and promoting standardized corporate management. The specific analysis is as follows: I. Legal Mandatory Requirements According to relevant laws and regulations such as the Regulations on the Supervision and Administration of Medical Devices, enterprises selling medical devices must obtain the corresponding Medical Device Business License. This is a mandatory regulatory measure by the state for the circulation of medical devices, aiming to ensure the safety, effectiveness, and traceability of products from the factory to consumers. Operating without a license will result in severe legal penalties, including confiscation of illegal gains, fines of up to 20 times the value of the goods (with a minimum of 50,000 yuan), and in serious cases, revocation of ...
- Source: drugdu
- 44
- February 2, 2026
J&J’s subcutaneous monoclonal antibody combination therapy receives further FDA approval; Autoimmune CAR-T therapy granted FDA Breakthrough Therapy Designation

J&J’s Subcutaneous Monoclonal Antibody Combination Therapy Receives Another FDA Approval. Recently, the U.S. FDA approved Johnson & Johnson’s subcutaneous formulation of its CD38-targeting monoclonal antibody, Darzalex Faspro® (daratumumab and hyaluronidase-fihj), in combination with bortezomib, lenalidomide, and dexamethasone (the VRd regimen). This combination is indicated for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). In the study, a total of 395 patients were randomized, with 197 receiving Darzalex Faspro in combination with VRd and 198 receiving VRd alone.
- Source: https://bydrug.pharmcube.com/news/detail/bb1becb2bd627f90903fc00877ae5c22
- 53
- February 2, 2026
Why is the development of AI-based antiviral drugs a niche field yet a necessity?

As AI-driven drug development moves beyond the initial stage of technical feasibility verification, technology and capital in the biopharmaceutical field are rapidly converging on this track, but this has also exacerbated the resource differentiation among different research directions: compared to the more popular drug development for oncology and autoimmune diseases due to AI support, there are very few AI-driven drug development projects launched in the already relatively quiet field of infectious disease drug development such as tuberculosis, malaria, and Nipah virus. 　　However, while AI-driven antiviral drug development is a niche area, it is a necessity. Currently, innovative drugs in the public health field…Drug development faces numerous challenges, including R&D investment far exceeding the “double ten cycle” (meaning that the average R&D cycle for an innovative drug from initiation to final market launch exceeds 10 years and the R&D cost exceeds $1 billion), greater uncertainty in commercial returns, scarcity of ...
- Source: https://finance.eastmoney.com/a/202601303636738175.html
- 58
- February 1, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.